110
Views
8
CrossRef citations to date
0
Altmetric
Original Articles

COMPARISON OF SPEEDY PCR-SSP METHOD AND SEROLOGICAL TYPING OF HLA-A24 FOR JAPANESE CANCER PATIENTS

, , , , , , , & show all
Pages 93-102 | Published online: 09 Mar 2011
 

Abstract

Human leukocyte antigen (HLA) typing is essential to carry out HLA-class I restricted antigenic peptide-based cancer immunotherapy. To establish a one-step polymerase chain reaction–sequence-specific primer (PCR-SSP) method, we designed two novel HLA-A24-specific primer sets and determined the optimal conditions for specific amplification. Then, we performed HLA-A24 typing of two healthy donors’ and 17 cancer patients’ peripheral blood with serological typing and PCR-SSP typing. Eleven of the 19 cases were determined HLA-A24-positive by the PCR-SSP method precisely; however, five cases showed false positive with serological analysis. Thus, for HLA-A24 typing in the Japanese population, the PCR-SSP method is faster and more accurate than serological typing.

ACKNOWLEDGMENTS

The authors thank Drs. P. G. Coulie and B. J. van den Eynde for kindly providing cell lines. This study was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science, and Technology of Japan. All authors have declared that there are no financial conflicts of interest in regard to this work.

Notes

n.d.: not detected.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.